These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 35132063)

  • 21. [Progress in the study of Her2-targeted cancer therapeutic antibodies].
    Chang L; Li CH; Gao J
    Yao Xue Xue Bao; 2015 May; 50(5):516-20. PubMed ID: 26234129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
    Patrick TA; Kranz DM; Zachary JF; Roy EJ
    Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The promise of bispecific antibodies: Clinical applications and challenges.
    Lim SM; Pyo KH; Soo RA; Cho BC
    Cancer Treat Rev; 2021 Sep; 99():102240. PubMed ID: 34119803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics.
    Qian L; Lin X; Gao X; Khan RU; Liao JY; Du S; Ge J; Zeng S; Yao SQ
    Chem Rev; 2023 Jun; 123(12):7782-7853. PubMed ID: 37186942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Engineering Antibodies as Drugs: Principles and Practice].
    Lugovskoy AA
    Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
    Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bispecific antibodies in onco-hematology: Applications and perspectives].
    Barrière S; El-Ghazzi N; Garcia M; Guièze R
    Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.
    Ghalamfarsa F; Khatami SH; Vakili O; Taheri-Anganeh M; Tajbakhsh A; Savardashtaki A; Fazli Y; Uonaki LR; Shabaninejad Z; Movahedpour A; Ghalamfarsa G
    Immunotherapy; 2021 Nov; 13(16):1355-1367. PubMed ID: 34641708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific antibodies and ADCs: Once and future kings?
    Reichert JM
    MAbs; 2011; 3(4):329-30. PubMed ID: 21654205
    [No Abstract]   [Full Text] [Related]  

  • 38. Emerging antibody-based therapies for the treatment of acute myeloid leukemia.
    Angenendt L; Mikesch JH; Schliemann C
    Cancer Treat Rev; 2022 Jul; 108():102409. PubMed ID: 35605472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
    Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
    Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.